4.7 Article

Development of chitosan nanocapsules containing essential oil of Matricaria chamomilla L. for the treatment of cutaneous leishmaniasis

Journal

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 162, Issue -, Pages 199-208

Publisher

ELSEVIER
DOI: 10.1016/j.ijbiomac.2020.06.149

Keywords

Nanocapsules; Chitosan; Matricaria chamomilla

Funding

  1. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [401286/2014-2 PVE]
  2. Science without Borders Program of CNPq
  3. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
  4. PRONEX/Fundacao Araucaria (Parana-Brazil)
  5. Financiadora de Estudos e Projetos (FINEP-Brazil)
  6. Programa de Pos-Graduacao em Ciencias Farmaceuticas da Universidade Estadual de Maringa
  7. Complexo de Centrais de Apoio a Pesquisa (COMCAP-UEM)
  8. CAPES-COFECUB program [Ph-C 911/18]

Ask authors/readers for more resources

Matricaria chamomilla L. has been used for centuries in many applications, including antiparasitic activity. Leishmaniasis is a parasitic disease, with limited treatments, due to high cost and toxicity. Thus, there is a need to develop new treatments, and in this context, natural products are targets of these researches. We report the development of chitosan nanocapsules containing essential oil of M. chamomilla (CEO) from oil-in-water emulsions using chitosan modified with tetradecyl chains as biocompatible shell material. The nanocapsules of CEO (NCEO) were analyzed by optical microscopy and dynamic light scattering, which revealed spherical shape and an average size of 800 nm. Successful encapsulation of CEO was further confirmed by fluorescence microscopy observations taking advantage of the autofluorescence properties of CEO. The encapsulation efficiency was around 90%. The entrapment of CEO reduced its cytotoxicity towards normal cells. On the other hand, the CEO was active against promastigotes and intracellular amastigotes, exhibiting IC50 of 3.33 pg/mL and 14.56 pg/mL, respectively, while NCEO showed IC50 for promastigotes of 7.18 pg/mL and for intracellular amastigotes of 14.29 pg/mL. These results demonstrate that encapsulation of CEO in nanocapsules using an alkylated chitosan biosurfactant as a green stabilizer is a promising therapeutic strategy to treat leishmaniasis. (c) 2020 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available